NF-κB-regulated, proinflammatory miRNAs in Alzheimer's disease

Alzheimer's Research and Therapy

Volumn 4, Issue 6, 2012, Pages

  Lukiw, Walter J ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ADAM10 ENDOPEPTIDASE; ALUMINUM; ANTAGOMIR; CAY 10512; CHELATING AGENT; FOSCARNET; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESYLIC ACID; MICRORNA 125B; MICRORNA 126; MICRORNA 146A; PENCICLOVIR; PHENSERINE; POLYPHENOL DERIVATIVE; RESVERATROL; SCAVENGER; UNCLASSIFIED DRUG; VALACICLOVIR;

3' UNTRANSLATED REGION; AGING; ALUMINUM OVERLOAD; ALZHEIMER DISEASE; ANATOMY; BRAIN CELL; CELL CYCLE ARREST; CELL PROLIFERATION; CREUTZFELDT JAKOB DISEASE; DOWN REGULATION; DOWN SYNDROME; EPIGENETICS; EPILEPTOGENESIS; FRONTAL CORTEX; GERSTMANN STRAUSSLER SCHEINKER SYNDROME; GLIA CELL; GLIOBLASTOMA; GLIOMA; HEALTH CARE; HERPES SIMPLEX VIRUS 1; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; NERVE CELL DEGENERATION; NERVE DEGENERATION; NONHUMAN; OCCIPITAL CORTEX; PARIETAL CORTEX; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; QUORUM SENSING; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE; UPREGULATION; VIRUS INFECTION;

EID: 84868663948     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt150     Document Type: Review

References (116)

1. A hundred years of Alzheimer's disease research. Hardy J, Neuron 2006 52 3 13 10.1016/j.neuron.2006.09.016 17015223
2. 100 years of AD research; are we any closer to a cure? Lukiw WJ, Aging Health 2007 3 279 282 10.2217/1745509X.3.3.279
3. Amyloid beta (A) peptide modulators and other current treatment strategies for Alzheimer's disease (AD). Lukiw WJ, Expert Opin Emerg Drugs 2012 22439907
4. Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid- peptide and s levels: target engagement, tolerability and pharmacokinetics in humans. Maccecchini ML, Chang MY, Pan C, John V, Zetterberg H, Greig NH, J Neurol Neurosurg Psychiatry 2012 83 894 902 10.1136/jnnp-2012- 302589 22791904
5. Whether, when and how chronic inflammation increases the risk of developing late-onset Alzheimer's disease. Eikelenboom P, Hoozemans JJ, Veerhuis R, van Exel E, Rozemuller AJ, van Gool WA, Alzheimers Res Ther 2012 4 15 26 10.1186/alzrt118 22647384
6. Natural secretory products of human neural and microvessel endothelial cells: implications in pathogenic 'spreading' and Alzheimer's disease. Zhao Y, Cui JG, Lukiw WJ, Mol Neurobiol 2006 34 181 192 10.1385/MN:34:3:181 17308351
7. Spreading of Alzheimer's disease inflammatory signaling through soluble micro-RNA. Lukiw WJ, Alexandrov PN, Zhao Y, Hill JM, Bhattacharjee S, Neuroreport 2012 23 621 626 10.1097/WNR.0b013e32835542b0 22660168
8. Regulation of complement factor H (CFH) by multiple miRNAs in Alzheimer's dsease (AD) brain. Lukiw WJ, Alexandrov PN, Mol Neurobiol 2012 46 11 19 10.1007/s12035-012-8234-4 22302353
9. Inflammatory, apoptotic, and survival gene signaling in Alzheimer's disease. A review on the bioactivity of neuroprotectin D1 and apoptosis. Lukiw WJ, Bazan NG, Mol Neurobiol 2010 42 10 16 10.1007/s12035-010-8126-4 20414817
10. Characterization of an NF-κB-regulated, miRNA-146a-mediated downregulation of complement factor H (CFH) in metal-sulfate-stressed human brain cells. Pogue AI, Li YY, Cui JG, Zhao Y, Kruck TP, Percy ME, Tarr MA, Lukiw WJ, J Inorg Biochem 2009 103 1591 1595 10.1016/j.jinorgbio.2009.05.012 19540598
11. Alzheimer's disease simulating an abscess of the left temporal lobe of the brain in a patient with chronic suppurative inflammation of the left middle ear. Katselson EN, Zh Ushn Nos Gorl Bolezn 1968 28 95 96 5747525
12. Inflammatory mechanisms in Alzheimer's disease. Eikelenboom P, Zhan SS, van Gool WA, Allsop D, Trends Pharmacol Sci 1994 15 447 450 10.1016/0165- 6147(94)90057-4 7886816
13. Inflammatory mechanisms in Alzheimer's disease: implications for therapy. Aisen PS, Davis KL, Am J Psychiatry 1994 151 1105 1113 7518651
14. NIH Medline Search; Keywords 'Inflammation, Alzheimer's Disease'. http://www.ncbi.nlm.nih.gov/gquery/?term=inflammation%20alzheimer%27s%20disease
15. Mitochondrial alterations, oxidative stress and neuroinflammation in Alzheimer's disease. Verri M, Pastoris O, Dossena M, Aquilani R, Guerriero F, Cuzzoni G, Venturini L, Ricevuti G, Bongiorno AI, Int J Immunopathol Pharmacol 2012 25 345 353 22697066
16. Expression of immunohistochemical markers on microglia in Creutzfeldt-Jakob disease and Alzheimer's disease: morphometric study and review of the literature. Wojtera M, Sobow T, Koszewska I, Liberski PP, Brown DR, Sikorska B, Folia Neuropathol 2012 50 74 84 22505366
17. Neuroinflammation in the aging down syndrome brain; lessons from Alzheimer's disease. Wilcock DM, Curr Gerontol Geriatr Res 2012 2012 170276 22454637
18. Epidemiological of and risk factors for Alzheimer's disease. Povova J, Ambroz P, Bar M, Pavukova V, Sery O, Tomaskova H, Janout V, Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2012 156 108 114 10.5507/bp.2012.055 22837131
19. An English translation of Alzheimer's 1907 paper 'Uber eine eigenartige Erkankung der Hirnrinde'. Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR, Clin Anat 1995 8 429 431 10.1002/ca.980080612 8713166
20. Alzheimer's disease: the amyloid cascade hypothesis: an update and reappraisal. Hardy J, J Alzheimers Dis 2006 9 151 153 16914853
21. Resolving controversies on the path to Alzheimer's therapeutics. Selkoe DJ, Nat Med 2011 17 1060 1065 10.1038/nm.2460 21900936
22. Vulnerability to Alzheimer's pathology in neocortex: the roles of plasticity and columnar organization. Esiri MM, Chance SA, J Alzheimers Dis 2006 9 79 89 16914847
23. Expression of inflammatory genes in the primary visual cortex of late-stage Alzheimer's disease. Cui JG, Hill JM, Zhao Y, Lukiw WJ, Neuroreport 2007 18 115 119 10.1097/WNR.0b013e32801198bc 17301674
24. Magnetic resonance imaging predictors of cognition in mild cognitive impairment. van de Pol LA, Korf ES, van der Flier WM, Brashear HR, Fox NC, Barkhof F, Scheltens P, Arch Neurol 2007 64 1023 1028 10.1001/archneur.64.7.1023 17620494
25. Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications. Marshall GA, Monserratt L, Harwood D, Mandelkern M, Cummings JL, Sultzer DL, Laforce R Jr, Rabinovici GD, Alzheimers Res Ther 2011 3 31 34 10.1186/alzrt93 22071129
26. Energy inhibition elevates betasecretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis. Velliquette RA, O'Connor T, Vassar R, J Neurosci 2005 25 10874 10883 10.1523/JNEUROSCI.2350-05.2005 16306400
27. Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia. Ewers M, Sperling RA, Klunk WE, Weiner MW, Hampel H, Trends Neurosci 2011 34 430 442 10.1016/j.tins.2011.05.005 21696834
28. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, Tariot P, Zoulnouni P, Galvin JE, Holtzman DM, Knopman DS, Satterwhite J, Gonzales C, Dean RA, May PC, Neurology 2006 66 602 604 10.1212/01.WNL. 0000198762.41312.E1 16505324
29. At the frontline of Alzheimer's disease treatment: gamma-secretase inhibitor/modulator mechanism. Tomita T, Naunyn Schmiedebergs Arch Pharmacol 2008 377 295 300 10.1007/s00210-007-0206-2 18038124
30. Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Siemers ER, Dean RA, Friedrich S, Ferguson-Sells L, Gonzales C, Farlow MR, May PC, Clin Neuropharmacol 2007 30 317 325 10.1097/WNF.0b013e31805b7660 18090456
31. Alpha, beta-and gamma-secretases in Alzheimer's disease. Epis R, Marcello E, Gardoni F, Luca MD, Front Biosci (Schol Ed) 2012 4 1126 1150 22202113
32. Current insights into molecular mechanisms of Alzheimer disease and their implications for therapeutic approaches. Van Broeck B, Van Broeckhoven C, Kumar-Singh S, Neurodegener Dis 2007 4 349 365 10.1159/000105156 17622778
33. Detection of miRNAs in microglia by real-time PCR in normal CNS and during neuroinflammation. Veremeyko T, Starossom SC, Weiner HL, Ponomarev ED, J Vis Exp 2012 23 65 71 22872097
34. The neuroimmune system in Alzheimer's disease: the glass is half full. Hickman SE, El Khoury J, J Alzheimers Dis 2012 22751176
35. Clearance of amyloid- peptides by microglia and macrophages: the issue of what, when and where. Lai AY, McLaurin J, Future Neurol 2012 7 165 176 10.2217/fnl.12.6 22737039
36. The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer's disease brain. Varnum MM, Ikezu T, Arch Immunol Ther Exp (Warsz) 2012 60 251 266 10.1007/s00005-012-0181-2
37. Manipulation of microglial activity as a therapy for Alzheimer's disease. Tan B, Choi RH, Chin TJ, Kaur C, Ling EA, Front Biosci (Schol Ed) 2012 4 1402 1412 22652882
38. An NF-κB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. Lukiw WJ, Zhao Y, Cui JG, J Biol Chem 2008 283 31315 31322 10.1074/jbc.M805371200 18801740
39. A review: inflammatory process in Alzheimer's disease, role of cytokines. Rubio-Perez JM, Morillas-Ruiz JM, Sci World J 2012 2012 756357 22566778
40. The origins of NF-κB. Sen R, Nat Immunol 2011 12 686 688 21772276
41. MicroRNAs, new effectors and regulators of NF-κB. Boldin MP, Baltimore D, Immunol Rev 2012 246 205 220 10.1111/j.1600-065X.2011.01089.x 22435557
42. Strong NF-κB-DNA binding parallels cyclooxygenase-2 gene transcription in aging and in sporadic Alzheimer's disease superior temporal lobe neocortex. Lukiw WJ, Bazan NG, J Neurosci Res 1998 53 583 592 10.1002/(SICI)1097-4547(19980901)53:5<583::AID-JNR8>3.0.CO;2-5 9726429
43. Coordinate activation of HIF-1 and NF-κB DNA binding and COX-2 and VEGF expression in retinal cells by hypoxia. Lukiw WJ, Ottlecz A, Lambrou G, Grueninger M, Finley J, Thompson HW, Bazan NG, Invest Ophthalmol Vis Sci 2003 44 4163 4170 10.1167/iovs.02-0655 14507857
44. Inflammatory cause of metabolic syndrome via brain stress and NF-κB. Cai D, Liu T, Aging (Albany NY) 2012 4 98 115 22328600
45. Hierarchies of NF-κB target-gene regulation. Smale ST, Nat Immunol 2011 12 689 694 21772277
46. NF-κB and innate immunity in ischemic stroke. Harari OA, Liao JK, Ann N Y Acad Sci 2010 1207 32 40 10.1111/j.1749-6632.2010.05735.x 20955423
47. NF-κB-mediated metabolic inflammation in peripheral tissues versus central nervous system. Cai D, Cell Cycle 2009 8 2542 2548 10.4161/cc.8.16.9386 19633416
48. Inflammation and NF-κB in Alzheimer's disease and diabetes. Granic I, Dolga AM, Nijholt IM, van Dijk G, Eisel UL, J Alzheimers Dis 2009 16 809 821 19387114
49. Differential regulation of interleukin-1 receptor-associated kinase-1 (IRAK-1) and IRAK-2 by microRNA-146a and NF-κB in stressed human astroglial cells and in Alzheimer disease. Cui JG, Li YY, Zhao Y, Bhattacharjee S, Lukiw WJ, J Biol Chem 2010 285 38951 38960 10.1074/jbc.M110.178848 20937840
50. BC200 and other small RNAs in normal human neocortex, non-Alzheimer dementia (NAD), and senile dementia of the Alzheimer type (AD). Lukiw WJ, Handley P, Wong L, McLachlan DRC, Neurochem Res 1992 17 591 597 10.1007/BF00968788 1603265
51. Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus. Lukiw WJ, Neuroreport 2007 18 297 300 10.1097/WNR.0b013e3280148e8b 17314675
52. MicroRNAs: target recognition and regulatory functions. Bartel DP, Cell 2009 136 215 233 10.1016/j.cell.2009.01.002 19167326
53. MicroRNA-146a and human disease. Li L, Chen XP, Li YJ, Scand J Immunol 2010 71 227 231 10.1111/j.1365-3083.2010.02383.x 20384865
54. Mammalian miRNAs act to decrease target mRNA levels. Guo H, Ingolia NT, Weissman JS, Bartel DP, Nature 2010 466 835 840 10.1038/nature09267 20703300
55. Expression of inflammatory genes in the primary visual cortex of late-stage Alzheimer's disease. Cui JG, Hill JM, Zhao Y, Lukiw WJ, Neuroreport 2007 18 115 119 10.1097/WNR.0b013e32801198bc 17301674
56. Up-regulation of micro RNA-146a (miRNA-146a), a marker for inflammatory neurodegeneration, in sporadic Creutzfeldt-Jakob disease (sCJD) and Gerstmann-Straussler Scheinker (GSS) syndrome. Lukiw WJ, Dua P, Pogue AI, Eicken C, Hill JM, J Toxicol Environ Health 2011 74 1460 1468 10.1080/15287394.2011. 618973
57. miRNA-125b (miRNA-125b) function in astrogliosis and glial cell proliferation. Pogue AI, Cui JG, Li YY, Zhao Y, Culicchia F, Lukiw WJ, Neurosci Lett 2010 476 18 22 10.1016/j.neulet.2010.03.054 20347935
58. Role of microRNAs in gliomagenesis: targeting miRNAs in glioblastoma multiforme therapy. Nikaki A, Piperi C, Papavassiliou AG, Expert Opin Investig Drugs 2012 21 1475 1488 10.1517/13543784.2012.710199 22809292
59. NF-κB-regulated micro RNAs (miRNAs) in primary human brain cells. Lukiw WJ, Exp Neurol 2012 235 484 490 10.1016/j.expneurol.2011.11.022 22138609
60. GeneCards: CDKN2A. http://www.genecards.org/cgi-bin/carddisp.pl?gene= CDKN2A
61. Synapsin regulation of vesicle organization and functional pools. Bykhovskaia M, Semin Cell Dev Biol 2011 22 387 392 10.1016/j.semcdb.2011.07.003 21827866
62. Synapsins: from synapse to network hyperexcitability and epilepsy. Fassio A, Raimondi A, Lignani G, Benfenati F, Baldelli P, Semin Cell Dev Biol 2011 22 408 415 10.1016/j.semcdb.2011.07.005 21816229
63. The synapsins: multitask modulators of neuronal development. Valtorta F, Pozzi D, Benfenati F, Fornasiero EF, Semin Cell Dev Biol 2011 22 378 386 10.1016/j.semcdb.2011.07.008 21798361
64. Defects in expression of genes related to synaptic vesicle trafficking in frontal cortex of Alzheimer's disease. Yao PJ, Zhu M, Pyun EI, Brooks AI, Therianos S, Meyers VE, Coleman PD, Neurobiol Dis 2003 12 97 109 10.1016/S0969-9961(02)00009-8 12667465
65. GeneCards: SYN2. http://www.genecards.org/cgi-bin/carddisp.pl?gene=SYN2
66. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, Serhan CN, Bazan NG, J Clin Invest 2005 115 2774 2783 10.1172/JCI25420 16151530
67. Docosahexaenoic acid and the aging brain. Lukiw WJ, Bazan NG, J Nutr 2008 138 2510 2514 10.3945/jn.108.096016 19022980
68. Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPAR-mediated mechanisms in Alzheimer's disease models. Zhao Y, Calon F, Julien C, Winkler JW, Petasis NA, Lukiw WJ, Bazan NG, PLoS One 2011 6 15816 10.1371/journal.pone.0015816 21246057
69. GeneCards: ALOX15. http://www.genecards.org/cgi-bin/carddisp.pl?gene= ALOX15
70. NF-κB-dependent induction of miRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Boldin MP, Chang KJ, Baltimore D, Proc Natl Acad Sci USA 2006 103 12481 12486 10.1073/pnas.0605298103 16885212
71. Inflammation and Alzheimer's disease. Lee YJ, Han SB, Nam SY, Oh KW, Hong JT, Arch Pharm Res 2010 33 1539 1556 10.1007/s12272-010-1006-7 21052932
72. Differential expression of miRNA-146a-regulated inflammatory genes in human primary neural, astroglial and microglial cells. Li YY, Cui JG, Dua P, Pogue AI, Bhattacharjee S, Lukiw WJ, Neurosci Lett 2011 499 109 113 10.1016/j.neulet.2011.05.044 21640790
73. HSV-1 infection of human brain cells induces miRNA-146a and Alzheimer-type inflammatory signaling. Hill JM, Zhao Y, Clement C, Neumann DM, Lukiw WJ, Neuroreport 2009 20 1500 1505 10.1097/WNR.0b013e3283329c05 19801956
74. Induction of specific micro RNA (miRNA) species by ROS-generating metal sulfates in primary human brain cells. Lukiw WJ, Pogue AI, J Inorg Biochem 2007 101 1265 1269 10.1016/j.jinorgbio.2007.06.004 17629564
75. GeneCards: CFH. http://www.genecards.org/cgi-bin/carddisp.pl?gene=CFH
76. The interleukin-1 receptor-associated kinases: critical regulators of innate immune signalling. Flannery S, Bowie AG, Biochem Pharmacol 2010 80 1981 1991 10.1016/j.bcp.2010.06.020 20599782
77. Regulations and roles of the interleukin-1 receptor associated kinases (IRAKs) in innate and adaptive immunity. Gan L, Li L, Immunol Res 2006 35 295 302 10.1385/IR:35:3:295 17172653
78. Expression profiling of mammalian miRNAs uncovers a subset of brainexpressed miRNAs with possible roles in murine and human neuronal diff erentiation. Sempere LF, Freemantle S, Pitha-Rowe I, Moss E, Dmitrovsky E, Ambros V, Genome Biol 2004 5 13 10.1186/gb-2004-5-3-r13 15003116
79. GeneCards: IRAK1. http://www.genecards.org/cgi-bin/carddisp.pl?gene=IRAK1
80. TSPAN12 regulates retinal vascular development by promoting Norrinbut not Wnt-induced FZD4/beta-catenin signaling. Junge HJ, Yang S, Burton JB, Paes K, Shu X, French DM, Costa M, Rice DS, Ye W, Cell 2009 139 299 311 10.1016/j.cell.2009.07.048 19837033
81. Tetraspanin12 regulates ADAM10-dependent cleavage of amyloid precursor protein. Xu D, Sharma C, Hemler ME, FASEB J 2009 23 3674 3681 10.1096/fj.09-133462 19587294
82. GeneCards: TSPAN12. http://www.genecards.org/cgi-bin/carddisp.pl?gene= TSPAN12
83. Up-regulation of NF-κB-sensitive miRNA-125b and miRNA-146a in metal sulfate-stressed human astroglial (HAG) primary cell cultures. Pogue AI, Percy ME, Cui JG, Li YY, Bhattacharjee S, Hill JM, Kruck TPA, Zhao Y, Lukiw WJ, J Inorganic Biochem 2011 105 1434 1437 10.1016/j.jinorgbio.2011.05.012
84. miRNA-155 up-regulation and complement factor H (CFH) deficits in Down's syndrome. Li YY, Alexandrov PN, Pogue AI, Zhao Y, Bhattacharjee S, Lukiw WJ, Neuroreport 2012 23 168 173 10.1097/WNR.0b013e32834f4eb4 22182977
85. Potential of anti-cancer therapy based on anti-miR-155 oligonucleotides in glioma and brain tumours. Poltronieri P, D'Urso PI, Mezzolla V, D'Urso OF, Chem Biol Drug Des 2012 doi: 10.1111/cbdd.12002 22834637
86. Expression pattern of miRNA-146a, an inflammation-associated microRNA, in experimental and human temporal lobe epilepsy. Aronica E, Fluiter K, Iyer A, Zurolo E, Vreijling J, van Vliet EA, Baayen JC, Gorter JA, Eur J Neurosci 2010 31 1100 1107 10.1111/j.1460-9568.2010.07122.x 20214679
87. Micro-RNA abundance and stability in human brain: specific alterations in Alzheimer's disease temporal lobe neocortex. Sethi P, Lukiw WJ, Neurosci Lett 2009 459 100 104 10.1016/j.neulet.2009.04.052 19406203
88. Acyclovir or A42 peptides attenuate HSV-1-induced miRNA-146a levels in human primary brain cells. Lukiw WJ, Cui JG, Yuan LY, Bhattacharjee PS, Corkern M, Clement C, Kammerman EM, Ball MJ, Zhao Y, Sullivan PM, Hill JM, Neuroreport 2010 21 922 927 10.1097/WNR.0b013e32833da51a 20683212
89. The high prevalence of herpes simplex virus type 1 DNA in human trigeminal ganglia is not a function of age or gender. Hill JM, Ball MJ, Neumann DM, Azcuy AM, Bhattacharjee PS, Bouhanik S, Clement C, Lukiw WJ, Foster TP, Kumar M, Kaufman HE, Thompson HW, J Virol 2008 82 8230 8234 10.1128/JVI.00686-08 18550674
90. Senile plaques in Alzheimer's disease brains: possible association of beta-amyloid with herpes simplex virus type 1 (HSV-1) L-particles. Kammerman EM, Neumann DM, Ball MJ, Lukiw W, Hill JM, Med Hypotheses 2006 66 294 299 10.1016/j.mehy.2005.07.033 16242250
91. Gene expression profiling in the HSV-1 latently infected mouse trigeminal ganglia following hyperthermic stress. Higaki S, Gebhardt B, Lukiw W, Thompson H, Hill J, Curr Eye Res 2003 26 231 238 10.1076/ceyr.26.3.231.14892 12815552
92. Gene expression analyzed by microarrays in HSV-1 latent mouse trigeminal ganglion following heat stress. Hill JM, Lukiw WJ, Gebhardt BM, Higaki S, Loutsch JM, Myles ME, Thompson HW, Kwon BS, Bazan NG, Kaufman HE, Virus Genes 2001 23 273 280 10.1023/A:1012517221937 11778695
93. Effect of immunosuppression on gene expression in the HSV-1 latently infected mouse trigeminal ganglion. Higaki S, Gebhardt BM, Lukiw WJ, Thompson HW, Hill JM, Invest Ophthalmol Vis Sci 2002 43 1862 1869 12036991
94. Antivirals reduce the formation of key Alzheimer's disease molecules in cell cultures acutely infected with herpes simplex virus type 1. Wozniak MA, Frost AL, Preston CM, Itzhaki RF, PLoS One 2011 6 25152 10.1371/journal.pone. 0025152 22003387
95. Could antivirals be used to treat Alzheimer's disease? Itzhaki RF, Wozniak MA, Future Microbiol 2012 7 307 309 10.2217/fmb.12.10 22393884
96. Intracerebral propagation of Alzheimer's disease confirms its herpes virus etiology. Ball MJ, Lukiw WJ, Kammerman E, Hill JM, Alzheimer's Dementia 2012 23155407
97. Pro-inflammatory effects of aluminum in human glioblastoma cells. Campbell A, Yang EY, Tsai-Turton M, Bondy SC, Brain Res 2002 933 60 65 10.1016/S0006-8993(02)02305-3 11929636
98. Aluminium, tau and Alzheimer's disease. Exley C, J Alzheimers Dis 2007 12 313 315 18198417
99. Aluminum disruption of calcium homeostasis and signal transduction resembles change that occurs in aging and Alzheimer's disease. Walton JR, J Alzheimers Dis 2012 29 255 273 22330830
100. Towards the prevention of potential aluminum toxic effects and an effective treatment for Alzheimer's disease. Percy ME, Kruck TP, Pogue AI, Lukiw WJ, J Inorg Biochem 2011 105 1505 1512 10.1016/j.jinorgbio.2011.08.001 22099160
101. Link between aluminum and the pathogenesis of Alzheimer's disease: the integration of the aluminum and amyloid cascade hypotheses. Kawahara M, Kato-Negishi M, Int J Alzheimers Dis 2011 2011 276393 21423554
102. Characterization of an NF-κB-regulated, miRNA-146a-mediated downregulation of complement factor H (CFH) in metal-sulfate-stressed human brain cells. Pogue AI, Li YY, Cui JG, Zhao Y, Kruck TP, Percy ME, Tarr MA, Lukiw WJ, J Inorg Biochem 2009 103 1591 1595 10.1016/j.jinorgbio.2009.05.012 19540598
103. APP/PS1 transgenic mice treated with aluminum: an update of Alzheimer's disease model. Zhang QL, Jia L, Jiao X, Guo WL, Ji JW, Yang HL, Niu Q, Int J Immunopathol Pharmacol 2012 25 49 58 22507317
104. Evidence supporting a biological role for aluminum in brain chromatin compaction and epigenetics. Lukiw WJ, J Inorg Biochem 2010 104 1010 1012 10.1016/j.jinorgbio.2010.05.007 20684046
105. Towards the prevention of potential aluminum toxic effects and an effective treatment for Alzheimer's disease. Percy ME, Kruck TP, Pogue AI, Lukiw WJ, J Inorg Biochem 2011 105 1505 1512 10.1016/j.jinorgbio.2011.08.001 22099160
106. Synergistic effects of iron and aluminum on stress-related gene expression in primary human neural cells. Alexandrov PN, Zhao Y, Pogue AI, Tarr MA, Kruck TP, Percy ME, Cui JG, Lukiw WJ, J Alzheimers Dis 2005 8 117 127 16308480
107. Nanomolar aluminum induces proinflammatory and pro-apoptotic gene expression in human brain cells in primary culture. Lukiw WJ, Percy ME, Kruck TP, J Inorg Biochem 2005 99 1895 1898 10.1016/j.jinorgbio.2005.04.021 15961160
108. Metalsulfate induced generation of ROS in human brain cells: detection using an isomeric mixture of 5- and 6-carboxy-2',7'-dichlorofluorescein diacetate (carboxy-DCFDA) as a cell permeant tracer. Pogue AI, Jones BM, Bhattacharjee S, Percy ME, Zhao Y, Lukiw WJ, Int J Mol Sci 2012 13 9615 9626 10.3390/ijms13089615 22949820
109. Molecular shuttle chelation: the use of ascorbate, desferrioxamine and Feralex-G in combination to remove nuclear bound aluminum. Kruck TP, Cui JG, Percy ME, Lukiw WJ, Cell Mol Neurobiol 2004 24 443 459 15206824
110. Synergistic effects of iron and aluminum on stress-related gene expression in primary human neural cells. Alexandrov PN, Zhao Y, Pogue AI, Tarr MA, Kruck TP, Percy ME, Cui JG, Lukiw WJ, J Alzheimers Dis 2005 8 117 127 16308480
111. Beyond amyloid: the future of therapeutics for Alzheimer's disease. Lane RF, Shineman DW, Steele JW, Lee LB, Fillit HM, Adv Pharmacol 2012 64 213 271 22840749
112. Molecular mechanism aspect of ER stress in Alzheimer's disease: current approaches and future strategies. Ansari N, Khodagholi F, Curr Drug Targets 2012
113. Treatment strategies targeting amyloid -protein. Schenk D, Basi GS, Pangalos MN, Cold Spring Harb Perspect Med 2012 2 006387 22951439
114. The blood-brain barrier in Alzheimer's disease: novel therapeutic targets and nanodrug delivery. Sharma HS, Castellani RJ, Smith MA, Sharma A, Int Rev Neurobiol 2012 102 47 90 22748826
115. MicroRNA turnover: when, how, and why. Rüegger S, Grohans H, Trends Biochem Sci 2012 37 436 446 10.1016/j.tibs.2012.07.002 22921610
116. MicroRNA degradation and turnover: regulating the regulators. Zhang Z, Qin YW, Brewer G, Jing Q, Wiley Interdiscip Rev RNA 2012 3 593 600 10.1002/wrna.1114 22461385